Drug Profile

Amifampridine - Jacobus Pharmaceutical

Alternative Names: 3-4DAP; Ruzurgi

Latest Information Update: 31 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jacobus Pharmaceutical
Developer Jacobus Pharmaceutical; Medunik Canada; ORSPEC Pharma
Class Aminopyridines; Antineoplastics; Small molecules
Mechanism of Action Acetylcholine stimulants; Potassium channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Lambert-Eaton myasthenic syndrome
New Molecular Entity No

Highest Development Phases

Registered Lambert-Eaton myasthenic syndrome

Most Recent Events

20 Mar 2025 Launched for Lambert-Eaton myasthenic syndrome (In the elderly, In adults) in USA (PO) before December 2024
31 Dec 2024 Withdrawn for Lambert-Eaton myasthenic syndrome (In the elderly, In adults) in USA (PO) before December 2024
12 Jul 2022 Catalyst Pharmaceuticals in-licenses development and marketing rights for Amifampridine from Jacobus Pharmaceutical in USA and Mexico

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com